HSD17B13 and metabolic dysfunction-associated steatotic liver disease: The application of post-transcriptional gene silencing using RNAi to suppress HSD17B13 expression has recently been introduced by Arrowhead (NCT04202354) and Alnylam Pharmaceuticals (NCT04565717) as a potential solution to treat NAFLD/NASH.